Will tazetostat be included in medical insurance reimbursement after it is launched in the country?

Tazemetostat As a new oralEZH2 inhibitor, it has quickly attracted attention in the global cancer treatment field since it was approved in the European and American markets, especially in the treatment of relapsed or refractory follicular lymphoma< /span> (FL; Non-Hodgkin lymphoma) and epithelioid sarcoma (ES; soft tissue sarcoma).

With its gradual introduction, registration and listing in China, the issue has attracted much attention from patients and the medical community. Whether the drug is covered by medical insurance has also become a focus of discussion. From the perspective of medical insurance access, whether innovative targeted drugs can enter the national or local medical insurance catalog usually depends on many factors, including clinical value, patient base, economic evaluation, and drug price negotiations.

As of now, the registration and approval of tazerestat in China is still in the clinical trial or initial marketing stage, and medical institutions in some cities may provide certain support to individual patients through special disease reimbursement policies. However, from the perspective of the national unified medical insurance directory, it has not yet entered the scope of routine reimbursement. This means that patients may have to bear a higher financial burden if they need to take the drug for a long time. Currently, some patients are taking medicine through imported channels or with the support of specific scientific research projects, but medical insurance coverage is still limited.

However, it can be expected that with the accumulation of data on tazetostat in the Chinese market and the improvement of domestic clinical consensus, its medical insurance prospects will gradually become clearer. Relevant departments are also actively promoting access negotiations for innovative drugs, especially if they meet the criteria of "urgent clinical needs and already on the market abroad", highly targeted drugs like tazerestat are expected to be included in the catalog with priority. Judging from the country's policy orientation to promote the management of malignant tumors and chronic diseases, EZH2 target drugs are in the scope of key evaluation. If price negotiations can be successful in the future, their inclusion in medical insurance may be gradually realized.

Reference materials:https://www.tazverik.com/